Angiotech Pharmaceuticals Announces Launch Of Quill SRS Product Codes For Laparoscopic Gynecology Procedures
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced the launch of a series of new, proprietary Quill(TM) SRS product codes specifically designed for laparoscopic, or minimally invasive, gynecology procedures, including hysterectomies and myomectomies. In 2008, there were approximately 750,000 hysterectomies performed in the United States of which approximately 130,000 were performed laparoscopically. In addition, there were approximately 72,000 myomectomies performed in the United States to remove uterine fibroid tumors. Management estimates 6-8% annual growth in laparoscopically assisted hysterectomies through 2014.
Medical Devices
Pages: 1 [2]
Blogs Comment On Supreme Court Decisions, Obama Administration, Other Topics
You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.Pages: 1 [2]